Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Hepatitis B Infection
Interventions
DRUG

Entecavir

Tablets, Oral, 0.5 mg, once daily, up to 52 weeks

Trial Locations (27)

7350

Local Institution, Belville

7460

Local Institution, Goodwood

10010

Va New York Harbor Healthcare System, New York

10701

Westchester Digestive Disease Group, Llp, Yonkers

13083

Local Institution, Campinas

14000

Local Institution, Df

19141

Albert Einstein Healthcare Network, Philadelphia

20037

George Washington University Medical Center, Washington D.C.

20210

Local Institution, Rio de Janeiro - Rj

20740

Banks Hepatology Institute, Pc, College Park

23249

Hunter Holmes Mcguire D V A M C, Richmond

30150

Local Institution, Belo Horizonte - Mg

33136

University Of Miami, Miami

33144

Empire International Research, Miami

36116

Alabama Liver & Digestive Specialists (Alds), Montgomery

40110

Local Institution, Salvador

44270

Local Institution, Guadalajara

44280

Local Institution, Guadalajara

44650

Local Institution, Guadalajara

45150

Local Institution, Zapopan

60637

University Of Chicago, Chicago

78215

Alamo Medical Research, San Antonio

85724

University Of Arizona, Tucson

02115

Brigham And Women'S Hospital, Boston

01107

L L C Bda The Research Institute, Springfield

01246

Local Institution, Sao Paulo - Sp

00909

Local Institution, Santurce

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY